XML 118 R99.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative and Other Relationships - Samsung Bioepis (Details)
$ in Millions
1 Months Ended 3 Months Ended
Dec. 31, 2019
product
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Collaborative arrangements and non-collaborative arrangement transactions        
Collaboration profit sharing/(loss reimbursement)   $ 65.6 $ 57.1  
Samsung Bioepis        
Collaborative arrangements and non-collaborative arrangement transactions        
Collaboration profit sharing/(loss reimbursement)   $ 60.6 $ 57.1  
Samsung Bioepis        
Collaborative arrangements and non-collaborative arrangement transactions        
Contingent Commercialized Rights, Number Of Products | product 2      
Expected profit share percentage 45.00% 50.00%    
Estimated additional payments upon achievement of development and commercial milestones   $ 180.0    
Collaboration agreement term   5 years    
Option exercise fee   $ 60.0    
Samsung Bioepis | Related Party        
Collaborative arrangements and non-collaborative arrangement transactions        
Accounts receivable   18.5   $ 9.9
Accounts payable   $ 35.6   $ 73.7